期刊论文

Effect of Risperidone Combined with Mirtazapine on Negative Symptom and Cognitive Impairment in Schizophrenia

中文

医学临床研究

1671-7171

2013

9

1755-1756,1759

10.3969/j.issn.1671-7171.2013.09.032

本校为第一机构

[目的]研究利培酮合并米氮平改善精神分裂症阴性症状与认知功能缺陷的效果。[方法]将60例正在服用利培酮治疗、阴性症状较明显（PANSS 阴性症状量表＞30分）的精神分裂症患者，随机分为利培酮（4 mg/d）联合并米氮平组（30 mg/d）（研究组，30例）和单用利培酮组（对照组，30例），治疗12周。分别于治疗前和治疗后第6周末及12周末进行阳性和阴性症状量表（PANSS）评分及认知功能测验。[结果]治疗后6周末及12周末，两组 PANSS 总分和阴性量表分较基线均有改善（P ＜0．05或 P ＜0．01）；研究组PNASS 总分及阴性症状量表分低于对照组，且两组比较差异有显著性（P ＜0．05）。治疗后12周末，两组部...

[Objective] To explore the efficacy of risperidone combined mirtazapine for improving negative symptom and cognitive impairment in schizophrenia. [Methods] Totally 60 patients with schizophrenia who were treated with risperidone and had prominent negative symptoms（negative subscale scores of PANSS〉30） were randomly divided into risperidone combined with mirtazapine（30mg/d） group（study group, n = 30） and single risperidone group（control group, n =30）. The treatment duration was 12 weeks. Positive and negative PANSS and cognitive measure...